Introduced in the 1990s as an effective treatment for acid reflux, proton-pump inhibitors (PPIs) such as omeprazole have become among the most commonly prescribed medications in the UK. Currently, around 10 million people regularly use these drugs, with the National Health Service (NHS) spending approximately £300 million annually on prescriptions. However, growing concerns have emerged about the long-term use of PPIs, which were originally intended for short-term symptom management.

PPIs work by suppressing stomach acid production, providing relief from the burning sensation and discomfort caused by acid reflux or gastro-oesophageal reflux disease (GORD). These conditions result from stomach acid leaking into the oesophagus, often due to a faulty valve or a hiatus hernia, and can cause inflammation, ulcers, and an increased risk of oesophageal cancer if untreated. While PPIs effectively reduce acid and help heal the oesophagus over several weeks, experts warn that they do not address the root causes of reflux.

Clinical gastrointestinal scientist Professor Anthony Hobson, with over three decades of experience, has described the widespread long-term use of PPIs as a significant problem. He points to evidence suggesting that prolonged use can disrupt the digestive system, alter the gut microbiome, and increase vulnerability to infections such as gastroenteritis and food poisoning. Additional studies have linked extended PPI use to conditions including chronic kidney disease, osteoporosis, certain cancers, mental health disorders, Parkinson’s disease, and dementia, although some of these associations remain under investigation.

Despite these risks, many patients remain on PPIs for years or even decades, often without regular medication reviews. Surveys indicate that a large proportion of patients—around one-third—have taken PPIs for more than five years, and one-fifth for ten years or longer. The tendency among general practitioners to prescribe PPIs readily, frequently without advising lifestyle or dietary changes, is cited as a factor contributing to over-reliance on these medications. For instance, fatty foods, caffeine, spicy and acidic foods, excess weight, and smoking are known to exacerbate reflux symptoms and may be managed with tailored lifestyle adjustments.

Medical authorities emphasize that PPIs should be used only for short-term treatment courses, typically six to eight weeks, followed by reassessment. Gradual dose reduction under medical supervision is advised when discontinuing PPIs to avoid rebound acid hypersecretion. Professor Hobson and other experts advocate for updated clinical guidelines to encourage healthcare providers to prioritize diet and lifestyle modifications before prescribing, conduct regular reviews of ongoing treatment, and better educate patients about potential side effects such as bloating, belching, diarrhoea, and repeated infections.

The Medicines and Healthcare products Regulatory Agency (MHRA) has noted that product information for PPIs recommends regular monitoring for patients on long-term therapy, especially beyond one year. Patients currently taking PPIs are advised to consult their doctors to discuss whether continued use is necessary and to explore other management options, including possible endoscopy and surgical interventions if indicated.

While PPIs remain valuable drugs when used appropriately for managing acid reflux and related conditions, growing calls for cautious prescribing and comprehensive patient management aim to balance their benefits against the emerging evidence of long-term risks.